Health Condition 1: null- Hypertension
Conditions
Interventions
None listed
Sponsors
Torrent Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patient willing to provide informed consent 2.Female or male patient aged 18 years or above 3.A treatment naive patient or a patient who are on treatment with other antihypertensive with grade 1 and 2 hypertension (SBP between 150 to 180) 4.Physician decides to prescribe azilsartan as a monotherapy or add-on 5.Patients must provide written consent to use personal and/or health data prior to the entry into the study
Exclusion criteria
Exclusion criteria: 1.Confirmed secondary hypertension 2.Patient taking a medicine acts upon RAAS e.g. ACEi or ARBs other than Azilsartan 3.Contraindications for azilsartan of respective approved local prescribing information. 4.Any reasons of medical and non-medical character, which in the opinion of the physician can prevent subject participation in the study 5.Pregnant and lactating woman and women of child bearing potential not ready to use an effective barrier contraceptive method during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To assess the mean change in clinic SBP and DBP levels from baseline to week 12Timepoint: At baseline At end of 12weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Percentage of Participants With Response. Response is defined as decrease of SBP â?¥20 mm Hg or decrease of DBP â?¥10 mm Hg. 2. Percentage of Participants who Achieve Target BP 140 mm Hg.Target BP is defined as SBP 140 mm Hg and DBP 90 mm Hg. 3.To understand usage pattern of azilsartan as monotherapy or add-on with other antihypertensive drugs 4.To assess adverse events during study durationTimepoint: At baseline At end of 12 weeks | — |
Countries
India
Contacts
Public ContactMr Altaf Makwana
Torrent Pharmaceuticals Ltd
Outcome results
None listed